Product liability bill
Executive Summary
Considered at Senate Judiciary Committee hearing on Aug. 5. Sponsored by Sen. Kasten (R-Wis.) and others, the product liablity law reform legislation (S 640) was debated on the Senate floor in May as an amendment to a "motor-voter" bill ("The Pink Sheet" May 18, In Brief). The Judiciary Committee asked for a hearing as a prerequisite to the measure's returning to the Senate floor for consideration as a free-standing bill, which is not likely to happen before September. The House Judiciary and Energy & Commerce Committees are not expected to consider a companion bill until the Senate passes S 640.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth